Journal profile · Pharmacology & Pharmacy
Recent Patents on Anti-Cancer Drug Discovery
ISSN 1574-8928 · eISSN 2212-3970 · Bentham Science Publishers B.V. · U ARAB EMIRATES · Tri-annual · Founded 2006
Recent Patents on Anti-Cancer Drug Discovery: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.39; hybrid open access; median 91 days to acceptance (39 articles, last 24 months); community-reported acceptance: fairly easy; 42 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Recent Patents on Anti-Cancer Drug Discovery is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diverse Scientific and Economic Studies, Legal Cases and Commentary and Intellectual Property and Patents, together about 33.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Aims & Scope Recent Patents on Anti-Cancer Drug Discovery publishes review and research articles that reflect or deal with studies in relation to a patent, application of reported patents in a study, discussion of comparison of results regarding application of a given patent, etc., and also guest edited thematic issues on recent patents in the field of anti-cancer drug discovery e.g. on novel bioactive compounds, analogs, targets & predictive biomarkers & drug efficacy biomarkers. The journal also publishes book reviews of eBooks and books on anti-cancer drug discovery. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-cancer drug discovery.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance15%
- Legal Cases and CommentaryMedicine9.6%
- Intellectual Property and PatentsBusiness, Management and Accounting9%
- Cancer Mechanisms and TherapyMedicine6%
- Ferroptosis and cancer prognosisMedicine4.4%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology4.1%
- Cancer Research and TreatmentMedicine3.7%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.39LetPub ·
- CiteScore 2026-06
- 5.6LetPub ·
- SJR 2026-06
- 0.64LetPub ·
- SNIP 2026-06
- 0.49LetPub ·
- h-index
- 36LetPub ·
- h-index
- 59OpenAlex ·
- i10-index
- 365OpenAlex ·
- 2-year mean citedness
- 1.76OpenAlex ·
- Self-citation rate
- 4.2%LetPub ·
- Share of gold OA articles
- 7.02%LetPub ·
Volume
- Articles per year
- 36LetPub ·
Articles by year OpenAlex count · 873 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 43 | 0 | 6 |
| 2025 | 42 | 3 | 49 |
| 2024 | 60 | 4 | 200 |
| 2023 | 58 | 6 | 307 |
| 2022 | 62 | 2 | 595 |
| 2021 | 87 | 9 | 982 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
91 daysMedian, submission to acceptance · P25–P75 68 days – 117 days
- Acceptance to online
- median 157 days (39 articles)
- Submission to online
- median 262 days
- Sample
- 39 articles with submission and acceptance dates (149 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- U ARAB EMIRATES
- Language
- English
- Frequency
- Tri-annual
- Founded
- 2006
- ISSN
- 1574-8928
- Electronic ISSN
- 2212-3970
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Recent Patents on Anti-Cancer Drug Discovery
What CAS zone is Recent Patents on Anti-Cancer Drug Discovery in?
In the 2025 upgraded edition of the CAS Journal Ranking, Recent Patents on Anti-Cancer Drug Discovery is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Recent Patents on Anti-Cancer Drug Discovery?
The latest impact factor listed by LetPub is 2.39; CiteScore 5.6, h-index 59.
How long does peer review take at Recent Patents on Anti-Cancer Drug Discovery?
Based on the dates recorded on 39 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 91 days (interquartile range 68–117 days); authors report an average review time of about 3 months; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Recent Patents on Anti-Cancer Drug Discovery?
According to LetPub and DOAJ records, Recent Patents on Anti-Cancer Drug Discovery is indexed in SCIE and Scopus.
Is Recent Patents on Anti-Cancer Drug Discovery open access, and what is the APC?
Recent Patents on Anti-Cancer Drug Discovery is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .